An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma

Date de début de l'étude : 1 mai 2004

Inclusion Criteria: * documented history of multiple myeloma, * failed at least two prior regimens for multiple myeloma, * 18 years of age or older, * ECOG(Zubrod)PS of 0 to 2, * screening evaluation for determining eligibility prior to enrollment, * signed informed consent form, Exclusion Criteria: * concomitant therapy medications including corticosteroids or other chemotherapy that is or may be active against myeloma , * renal insufficiency (serum creatinine levels of \> 2mg/dL), * mucosal bleeding, * any condition which in the opinion of the Investigator, places the patient at unacceptable risk if he/she were to participate in the study. * clinically relevant active infection or co-morbid medical conditions. * prior malignancy(within the last 3 years) except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient is has been disease-free for at least 3 years. * patients with non-secretory myeloma. * as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be excluded.